Risk of left ventricular assist device driveline infection: A systematic literature review

Background

Left ventricular assist devices (LVADs) improve quality of life in end-stage heart failure but can cause serious complications such as infections with driveline infection causing significant morbidity and mortality.

沙利度胺联合VAD方案治疗老年多发性骨髓瘤患者的临床效果

【】 目的 研究老年多发性骨髓瘤患者采取沙利度胺与VAD治疗的临床价值。方法 选择我院和深圳市宝安区人民医院2008年12月-2017年4月纳入的60例老年多发性骨髓瘤患者,按照随机数字法分为研究组与对照组各30例,研究组采取沙利度胺与VAD,对照组采取VAD,对比两组临床治疗效果。结果 研究组总有效率90.00%高于对照组76.67%(P＜0.05);两组治疗前相关指标变化情况比较,差异无统计学意义(P>0.05),研究组治疗后的β2-微球蛋白、M蛋白、骨髓瘤细胞水平低于对照组,血红蛋白水平高于对照组(P＜0.05);两组治疗前的生活质量水平比较,差异无统计学意义(P>0.05),研究组治疗后的环境因素、躯体状况、心理健康以及社会关系评分高于对照组(P＜0.05);研究组不良反应发生率10.00%低于对照组26.67%(P＜0.05)。结论 老年多发性骨髓瘤患者采取沙利度胺与VAD治疗效果显著,明显改善相关指标水平,提高生活质量,减少不良反应发生率,安全性高。     

基于发明专利的全球心室辅助装置技术创新态势研究

目的:研究全球心室辅助装置(VAD)领域的发明专利,分析揭示技术创新态势,为VAD领域的研发提供信息支撑.方法:采用专利分析方法,从技术创新时间趋势、技术创新热点、技术创新国家和地区以及主要竞争对手等角度,对智慧芽专利数据库收录的VAD发明专利进行分析,揭示VAD领域的发展态势.结果:VAD领域目前共有发明专利申请11...     

联合化疗治疗多发性骨髓瘤临床分析

目的探讨沙利度胺联合VAD方案治疗多发性骨髓瘤的可行性及安全性。方法将67例多发性骨髓瘤患者随机分为对照组32例和治疗组35例:对照组单用VAD方案化疗,治疗组在VAD方案基础上加用沙利度胺片,起始量100mg/d,每晚顿服或分早晚给药,根据患者耐受情况每2周增加100mg,最高剂量不超过600mg/d,维持此剂量6个月。观察两组临床疗效及不良反应。结果治疗组和对照组总有效率分别为82.9%和53.1%。两组总有效率比较,差异有统计学意义(P<0.05)。两组均无明显肝、肾功能损害及骨髓抑制,不良反应在对症处理后,症状均较快缓解。两组间不良反应比较,差异无统计学意义(P>0.05)。结论沙利度胺联合VAD方案治疗多发性骨髓瘤具有耐受性好、疗效肯定、不良反应少等优点,值得临床推广应用。     

沙立度胺联合VAD方案治疗多发性骨髓瘤22例疗效观察

目的观察采用沙立度胺联合VAD方案治疗初发多发性骨髓瘤（MM）患者的临床疗效。方法对22例初发MM患者采用沙立度胺联合VAD方案化疗,每21d为1个疗程,1个疗程后间歇4周,观察疗效及药物毒副反应。结果治疗3个疗程后,22例患者部分缓解27．2％（6／22）、进步54．5％（12／22）、总有效率为81．8％（18／22）。毒副反应为骨髓抑制,指端麻木及便秘等。结论沙立度胺联合VAD方案治疗初发MM患者疗效较好,值得临床推广。     

沙利度胺联合VAD治疗多发性骨髓瘤的血清VEGF变化

目的 探讨沙利度胺联合VAD方案治疗多发性骨髓瘤（multiple myeloma，MM）的临床疗效及治疗前后血管内皮生长因子（vascular endothelial growth factor，VEGF）水平变化。方法 28例MM患者，其中初治组14例，复发难治组14例，采用沙利度胺联合VAD方案治疗，在治疗前后测定每一例患者VEGF水平。结果 初治组14例：部分缓解10例，进步2例，总有效率85．7％，复发难治组14例，部分缓解6例，进步3例，总有效率64．3％。经检验差异有显著性（P〈0.05）。多发性骨髓瘤患者血清VEGF水平与疾病的活动情况相关，化疗有效者血清VEGF水平明显下降（P〈0．05），而化疗无效者则下降不明显（P〉0.05）。结论 沙利度胺联合VAD方案治疗多发性骨髓瘤具有副作用少，耐受性好，给药方便，疗效明显的优点，值得临床推广应用。     

Segmented polyurethane modified by photopolymerization and cross-linking with 2-methacryloyloxyethyl phosphorylcholine polymer for blood-contacting surfaces of ventricular assist devices

To improve the biocompatibility of pulsatile ventricular assist devices (VADs), the blood-contacting surface of the segmented polyurethane (SPU) diaphragm employed in an electromechanical VAD was modified by introducing 2-methacryloyloxyethyl phosphorylcholine (MPC) units into its surface and forming an interpenetrating polymer network (IPN) structure, which contained independently cross-linked MPC polymer and SPU. The SPU diaphragm modified with an IPN structure was then assembled into a target test pump and underwent continuous pump operation at 37°C for 2 weeks in a simulated systemic circulation using a mock circulatory loop. The surface characteristics of the pump diaphragm after 2 weeks of pump operation were then analyzed with an X-ray photoelectron spectroscope (XPS) and gold-colloid-labeled immunoassay. The XPS surface analysis of the IPN-modified SPU indicated the firm anchoring of MPC units even after 2 weeks of pump operation (the phosphor : carbon ratio was reduced by only 0.09%). The IPN-modified diaphragm prevented protein adsorption as well as cell adhesion in comparison to the unmodified SPU surface. This result thus validated that (1) the IPN structure could firmly secure MPC units to the SPU surface even in a high-mechanical-stress and high-shear environment, (2) the antithrombogenic power of MPC units remained unchanged after 2 weeks of continuous exposure to a high-shear environment, and (3) the IPN modified SPU cross-linked with MPC could be a powerful antithrombogenic surface for blood pumps used for chronic circulatory support of cardiac patients.     

Caspase‐2L,caspase‐9, and caspase‐3 during in vitro maturation and fragmentation of the mouse oocyte

Several studies have shown that apoptotic pathways control fragmentation of unfertilized ovulated oocyte, induced by doxorubicin. But very few have investigated the basis of this process, from prophase I to later stages. Our results revealed the presence of caspase‐2_L, caspase‐9, and caspase‐3 in their zymogen and cleaved forms in the oocyte before meiosis resumption. Caspase‐2_L and caspase‐9 were detected in the nucleus of GV‐oocytes in a distribution related to chromatin configuration. The inhibition of caspase activity by Z‐VAD‐fmk accelerated the transition from metaphase I to metaphase II, and caspase‐9 and caspase‐3 were detected along the meiotic spindle. Surprisingly, Western blot analysis revealed that the three cleaved caspases were present in similar amounts in healthy and fragmented oocytes and caspase inhibition did not prevent doxorubicin‐induced apoptosis. Our results suggest that, if cleaved, caspases may be dispensable for final oocyte death and they could be involved in regulating the maturation process. Developmental Dynamics 237:3892–3903, 2008. © 2008 Wiley‐Liss, Inc.     

沙利度胺联合VAD方案治疗复发难治性多发性骨髓瘤10例临床观察

多发性骨髓瘤(MM)是一种常见的血液系统恶性肿瘤,老年人多见,其特征是单克隆浆细胞恶性增生并分泌大量单可隆免疫球蛋白或其片断(M蛋白),同时伴有广泛的溶骨病变或骨质疏松及贫血、感染、肾功能损害等临床表现。化学治疗仍是目前治疗多